> top > docs > PubMed:18165598 > annotations

PubMed:18165598 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCoin-entities

Id Subject Object Predicate Lexical cue db_id
4613 28-39 ChemicalEntity denotes bupivacaine MESH:D002045
4614 44-53 ChemicalEntity denotes lidocaine MESH:D008012
4615 57-73 GeneOrGeneProduct denotes prostaglandin E2 NCBIGene:5732
4616 83-97 GeneOrGeneProduct denotes cyclooxygenase NCBIGene:4512|NCBIGene:4513
4617 118-122 DiseaseOrPhenotypicFeature denotes pain MESH:D010146
4618 137-141 DiseaseOrPhenotypicFeature denotes pain MESH:D010146
4619 278-290 DiseaseOrPhenotypicFeature denotes inflammation MESH:D007249
4620 357-368 ChemicalEntity denotes bupivacaine MESH:D002045
4621 378-394 GeneOrGeneProduct denotes prostaglandin E2 NCBIGene:5732
4622 396-400 GeneOrGeneProduct denotes PGE2 NCBIGene:5732
4623 417-431 GeneOrGeneProduct denotes cyclooxygenase NCBIGene:4512|NCBIGene:4513
4624 433-436 GeneOrGeneProduct denotes COX NCBIGene:4512|NCBIGene:4513
4625 469-487 DiseaseOrPhenotypicFeature denotes postoperative pain MESH:D010149
4626 491-496 OrganismTaxon denotes human NCBITaxon:9606
4627 601-610 ChemicalEntity denotes lidocaine MESH:D008012
4628 619-630 ChemicalEntity denotes bupivacaine MESH:D002045
4629 657-666 ChemicalEntity denotes rofecoxib MESH:C116926
4630 889-893 GeneOrGeneProduct denotes PGE2 NCBIGene:5732
4631 898-912 ChemicalEntity denotes thromboxane B2 MESH:D013929
4632 914-918 ChemicalEntity denotes TXB2 MESH:D013929
4633 947-958 ChemicalEntity denotes bupivacaine MESH:D002045
4634 959-968 ChemicalEntity denotes rofecoxib MESH:C116926
4635 1003-1007 DiseaseOrPhenotypicFeature denotes pain MESH:D010146
4636 1127-1138 ChemicalEntity denotes bupivacaine MESH:D002045
4637 1181-1185 DiseaseOrPhenotypicFeature denotes pain MESH:D010146
4638 1198-1202 GeneOrGeneProduct denotes PGE2 NCBIGene:5732
4639 1306-1317 ChemicalEntity denotes bupivacaine MESH:D002045
4640 1342-1347 GeneOrGeneProduct denotes COX-2 NCBIGene:4513
4641 1393-1402 ChemicalEntity denotes lidocaine MESH:D008012
4642 1418-1429 ChemicalEntity denotes Thromboxane MESH:D013931
4643 1563-1568 GeneOrGeneProduct denotes COX-2 NCBIGene:4513
4644 1578-1583 GeneOrGeneProduct denotes COX-1 NCBIGene:4512
4645 1625-1636 ChemicalEntity denotes bupivacaine MESH:D002045
4646 1648-1653 GeneOrGeneProduct denotes COX-2 NCBIGene:4513
4647 1676-1689 DiseaseOrPhenotypicFeature denotes tissue injury MESH:D017695
4648 1723-1727 GeneOrGeneProduct denotes PGE2 NCBIGene:5732
4649 1743-1747 DiseaseOrPhenotypicFeature denotes pain MESH:D010146

LitCoin-sentences

Id Subject Object Predicate Lexical cue
T1 0-148 Sentence denotes The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
T2 149-160 Sentence denotes BACKGROUND:
T3 161-291 Sentence denotes In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate inflammation.
T4 292-506 Sentence denotes In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
T5 507-515 Sentence denotes METHODS:
T6 516-740 Sentence denotes Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h.
T7 741-812 Sentence denotes Oral mucosal biopsies were taken before surgery and 48 h after surgery.
T8 813-933 Sentence denotes After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 (TXB2) measurements.
T9 934-942 Sentence denotes RESULTS:
T10 943-1113 Sentence denotes The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h.
T11 1114-1295 Sentence denotes However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
T12 1296-1417 Sentence denotes Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group.
T13 1418-1584 Sentence denotes Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1.
T14 1585-1597 Sentence denotes CONCLUSIONS:
T15 1598-1793 Sentence denotes These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.

LitCoin-entities-OrganismTaxon-PD

Id Subject Object Predicate Lexical cue db_id
T1 491-496 OrganismTaxon denotes human NCBItxid:9606

LitCoin_Mondo

Id Subject Object Predicate Lexical cue mondo_id
T1 746-753 DiseaseOrPhenotypicFeature denotes mucosal 0020579
T2 1683-1689 DiseaseOrPhenotypicFeature denotes injury 0021178

LitCoin-GeneOrGeneProduct-v0

Id Subject Object Predicate Lexical cue
T1 83-97 GeneOrGeneProduct denotes cyclooxygenase
T2 118-122 GeneOrGeneProduct denotes pain
T3 137-141 GeneOrGeneProduct denotes pain
T4 176-184 GeneOrGeneProduct denotes blocking
T5 224-228 GeneOrGeneProduct denotes long
T6 229-235 GeneOrGeneProduct denotes acting
T7 396-400 GeneOrGeneProduct denotes PGE2
T8 402-412 GeneOrGeneProduct denotes production
T9 417-431 GeneOrGeneProduct denotes cyclooxygenase
T10 433-436 GeneOrGeneProduct denotes COX
T11 483-487 GeneOrGeneProduct denotes pain
T12 507-514 GeneOrGeneProduct denotes METHODS
T13 560-568 GeneOrGeneProduct denotes impacted
T14 670-672 GeneOrGeneProduct denotes mg
T15 889-893 GeneOrGeneProduct denotes PGE2
T16 910-912 GeneOrGeneProduct denotes B2
T17 1003-1007 GeneOrGeneProduct denotes pain
T18 1065-1070 GeneOrGeneProduct denotes other
T19 1181-1185 GeneOrGeneProduct denotes pain
T20 1198-1202 GeneOrGeneProduct denotes PGE2
T21 1266-1271 GeneOrGeneProduct denotes other
T22 1342-1347 GeneOrGeneProduct denotes COX-2
T23 1342-1345 GeneOrGeneProduct denotes COX
T24 1563-1568 GeneOrGeneProduct denotes COX-2
T25 1563-1566 GeneOrGeneProduct denotes COX
T26 1578-1583 GeneOrGeneProduct denotes COX-1
T27 1578-1581 GeneOrGeneProduct denotes COX
T28 1648-1653 GeneOrGeneProduct denotes COX-2
T29 1648-1651 GeneOrGeneProduct denotes COX
T30 1723-1727 GeneOrGeneProduct denotes PGE2
T31 1728-1738 GeneOrGeneProduct denotes production
T32 1743-1747 GeneOrGeneProduct denotes pain

LitCoin-GeneOrGeneProduct-v2

Id Subject Object Predicate Lexical cue
T1 83-97 GeneOrGeneProduct denotes cyclooxygenase
T2 118-122 GeneOrGeneProduct denotes pain
T3 137-141 GeneOrGeneProduct denotes pain
T4 396-400 GeneOrGeneProduct denotes PGE2
T5 417-431 GeneOrGeneProduct denotes cyclooxygenase
T6 433-436 GeneOrGeneProduct denotes COX
T7 483-487 GeneOrGeneProduct denotes pain
T8 889-893 GeneOrGeneProduct denotes PGE2
T9 1003-1007 GeneOrGeneProduct denotes pain
T10 1065-1070 GeneOrGeneProduct denotes other
T11 1181-1185 GeneOrGeneProduct denotes pain
T12 1198-1202 GeneOrGeneProduct denotes PGE2
T13 1266-1271 GeneOrGeneProduct denotes other
T14 1342-1347 GeneOrGeneProduct denotes COX-2
T15 1342-1345 GeneOrGeneProduct denotes COX
T16 1563-1568 GeneOrGeneProduct denotes COX-2
T17 1563-1566 GeneOrGeneProduct denotes COX
T18 1578-1583 GeneOrGeneProduct denotes COX-1
T19 1578-1581 GeneOrGeneProduct denotes COX
T20 1648-1653 GeneOrGeneProduct denotes COX-2
T21 1648-1651 GeneOrGeneProduct denotes COX
T22 1723-1727 GeneOrGeneProduct denotes PGE2
T23 1743-1747 GeneOrGeneProduct denotes pain

LitCoin-Disease-MeSH

Id Subject Object Predicate Lexical cue originalLabel
T1 118-122 DiseaseOrPhenotypicFeature denotes pain D010146
T2 137-141 DiseaseOrPhenotypicFeature denotes pain D010146
T3 278-290 DiseaseOrPhenotypicFeature denotes inflammation D007249
T4 330-345 DiseaseOrPhenotypicFeature denotes proinflammatory DISEASE
T5 469-487 DiseaseOrPhenotypicFeature denotes postoperative pain D010149
T6 1003-1007 DiseaseOrPhenotypicFeature denotes pain D010146
T7 1181-1185 DiseaseOrPhenotypicFeature denotes pain D010146
T8 1683-1689 DiseaseOrPhenotypicFeature denotes injury D014947
T9 1743-1747 DiseaseOrPhenotypicFeature denotes pain D010146

LitCoin_Mondo_095

Id Subject Object Predicate Lexical cue mondo_id
T1 1683-1689 DiseaseOrPhenotypicFeature denotes injury 0021178

LitCoin-MeSH-Disease-2

Id Subject Object Predicate Lexical cue ID:
T1 118-122 DiseaseOrPhenotypicFeature denotes pain D010146
T2 137-141 DiseaseOrPhenotypicFeature denotes pain D010146
T3 278-290 DiseaseOrPhenotypicFeature denotes inflammation DISEASE|D007249
T5 330-345 DiseaseOrPhenotypicFeature denotes proinflammatory DISEASE
T6 469-487 DiseaseOrPhenotypicFeature denotes postoperative pain D010149
T7 1003-1007 DiseaseOrPhenotypicFeature denotes pain D010146
T8 1181-1185 DiseaseOrPhenotypicFeature denotes pain D010146
T9 1683-1689 DiseaseOrPhenotypicFeature denotes injury D014947
T10 1743-1747 DiseaseOrPhenotypicFeature denotes pain D010146

LitCoin-MONDO_bioort2019

Id Subject Object Predicate Lexical cue #label
T1 118-122 DiseaseOrPhenotypicFeature denotes pain D010146
T2 137-141 DiseaseOrPhenotypicFeature denotes pain D010146
T3 278-290 DiseaseOrPhenotypicFeature denotes inflammation D007249
T4 330-345 DiseaseOrPhenotypicFeature denotes proinflammatory DISEASE
T5 469-487 DiseaseOrPhenotypicFeature denotes postoperative pain D010149
T6 1003-1007 DiseaseOrPhenotypicFeature denotes pain D010146
T7 1181-1185 DiseaseOrPhenotypicFeature denotes pain D010146
T8 1743-1747 DiseaseOrPhenotypicFeature denotes pain D010146

LitCoin-Chemical-MeSH-CHEBI

Id Subject Object Predicate Lexical cue ID:
T1 28-39 ChemicalEntity denotes bupivacaine D002045|http://purl.obolibrary.org/obo/CHEBI_3215
T3 44-53 ChemicalEntity denotes lidocaine D008012|http://purl.obolibrary.org/obo/CHEBI_6456
T5 57-73 ChemicalEntity denotes prostaglandin E2 http://purl.obolibrary.org/obo/CHEBI_606564|http://purl.obolibrary.org/obo/CHEBI_15551
T7 83-97 ChemicalEntity denotes cyclooxygenase D011451
T8 357-368 ChemicalEntity denotes bupivacaine D002045|http://purl.obolibrary.org/obo/CHEBI_3215
T10 378-394 ChemicalEntity denotes prostaglandin E2 http://purl.obolibrary.org/obo/CHEBI_606564|http://purl.obolibrary.org/obo/CHEBI_15551
T12 396-400 ChemicalEntity denotes PGE2 D015232|http://purl.obolibrary.org/obo/CHEBI_15551|http://purl.obolibrary.org/obo/CHEBI_606564
T15 417-431 ChemicalEntity denotes cyclooxygenase D011451
T16 433-436 ChemicalEntity denotes COX D011451
T17 601-610 ChemicalEntity denotes lidocaine D008012|http://purl.obolibrary.org/obo/CHEBI_6456
T19 619-630 ChemicalEntity denotes bupivacaine D002045|http://purl.obolibrary.org/obo/CHEBI_3215
T21 657-666 ChemicalEntity denotes rofecoxib C116926|http://purl.obolibrary.org/obo/CHEBI_8887
T23 889-893 ChemicalEntity denotes PGE2 D015232|http://purl.obolibrary.org/obo/CHEBI_15551|http://purl.obolibrary.org/obo/CHEBI_606564
T26 898-912 ChemicalEntity denotes thromboxane B2 http://purl.obolibrary.org/obo/CHEBI_90696|http://purl.obolibrary.org/obo/CHEBI_28728
T28 914-918 ChemicalEntity denotes TXB2 http://purl.obolibrary.org/obo/CHEBI_28728|http://purl.obolibrary.org/obo/CHEBI_90696
T30 947-958 ChemicalEntity denotes bupivacaine D002045|http://purl.obolibrary.org/obo/CHEBI_3215
T32 959-968 ChemicalEntity denotes rofecoxib C116926|http://purl.obolibrary.org/obo/CHEBI_8887
T34 1127-1138 ChemicalEntity denotes bupivacaine D002045|http://purl.obolibrary.org/obo/CHEBI_3215
T36 1198-1202 ChemicalEntity denotes PGE2 D015232|http://purl.obolibrary.org/obo/CHEBI_15551|http://purl.obolibrary.org/obo/CHEBI_606564
T39 1306-1317 ChemicalEntity denotes bupivacaine D002045|http://purl.obolibrary.org/obo/CHEBI_3215
T41 1342-1345 ChemicalEntity denotes COX D011451
T42 1393-1402 ChemicalEntity denotes lidocaine D008012|http://purl.obolibrary.org/obo/CHEBI_6456
T44 1418-1429 ChemicalEntity denotes Thromboxane D013931|http://purl.obolibrary.org/obo/CHEBI_26995
T46 1563-1566 ChemicalEntity denotes COX D011451
T47 1578-1581 ChemicalEntity denotes COX D011451
T48 1625-1636 ChemicalEntity denotes bupivacaine D002045|http://purl.obolibrary.org/obo/CHEBI_3215
T50 1648-1651 ChemicalEntity denotes COX D011451
T51 1723-1727 ChemicalEntity denotes PGE2 D015232|http://purl.obolibrary.org/obo/CHEBI_15551|http://purl.obolibrary.org/obo/CHEBI_606564

LitCoin-NCBITaxon-2

Id Subject Object Predicate Lexical cue
T1 491-496 OrganismTaxon denotes human

LitCoin-GeneOrGeneProduct-v3

Id Subject Object Predicate Lexical cue
T1 83-97 GeneOrGeneProduct denotes cyclooxygenase
T2 396-400 GeneOrGeneProduct denotes PGE2
T3 417-431 GeneOrGeneProduct denotes cyclooxygenase
T4 433-436 GeneOrGeneProduct denotes COX
T5 889-893 GeneOrGeneProduct denotes PGE2
T6 1198-1202 GeneOrGeneProduct denotes PGE2
T7 1342-1347 GeneOrGeneProduct denotes COX-2
T9 1563-1568 GeneOrGeneProduct denotes COX-2
T11 1578-1583 GeneOrGeneProduct denotes COX-1
T13 1648-1653 GeneOrGeneProduct denotes COX-2
T15 1723-1727 GeneOrGeneProduct denotes PGE2

LitCoin-training-merged

Id Subject Object Predicate Lexical cue #label ID:
T51 1723-1727 ChemicalEntity denotes PGE2 http://purl.obolibrary.org/obo/CHEBI_606564|http://purl.obolibrary.org/obo/CHEBI_15551|D015232
T50 1648-1651 ChemicalEntity denotes COX D011451
T48 1625-1636 ChemicalEntity denotes bupivacaine http://purl.obolibrary.org/obo/CHEBI_3215|D002045
T47 1578-1581 ChemicalEntity denotes COX D011451
T46 1563-1566 ChemicalEntity denotes COX D011451
T44 1418-1429 ChemicalEntity denotes Thromboxane http://purl.obolibrary.org/obo/CHEBI_26995|D013931
T42 1393-1402 ChemicalEntity denotes lidocaine http://purl.obolibrary.org/obo/CHEBI_6456|D008012
T41 1342-1345 ChemicalEntity denotes COX D011451
T39 1306-1317 ChemicalEntity denotes bupivacaine http://purl.obolibrary.org/obo/CHEBI_3215|D002045
T36 1198-1202 ChemicalEntity denotes PGE2 http://purl.obolibrary.org/obo/CHEBI_606564|http://purl.obolibrary.org/obo/CHEBI_15551|D015232
T34 1127-1138 ChemicalEntity denotes bupivacaine http://purl.obolibrary.org/obo/CHEBI_3215|D002045
T32 959-968 ChemicalEntity denotes rofecoxib http://purl.obolibrary.org/obo/CHEBI_8887|C116926
T30 947-958 ChemicalEntity denotes bupivacaine http://purl.obolibrary.org/obo/CHEBI_3215|D002045
T28 914-918 ChemicalEntity denotes TXB2 http://purl.obolibrary.org/obo/CHEBI_90696|http://purl.obolibrary.org/obo/CHEBI_28728
T26 898-912 ChemicalEntity denotes thromboxane B2 http://purl.obolibrary.org/obo/CHEBI_28728|http://purl.obolibrary.org/obo/CHEBI_90696
T23 889-893 ChemicalEntity denotes PGE2 http://purl.obolibrary.org/obo/CHEBI_606564|http://purl.obolibrary.org/obo/CHEBI_15551|D015232
T21 657-666 ChemicalEntity denotes rofecoxib http://purl.obolibrary.org/obo/CHEBI_8887|C116926
T19 619-630 ChemicalEntity denotes bupivacaine http://purl.obolibrary.org/obo/CHEBI_3215|D002045
T17 601-610 ChemicalEntity denotes lidocaine http://purl.obolibrary.org/obo/CHEBI_6456|D008012
T16 433-436 ChemicalEntity denotes COX D011451
T15 417-431 ChemicalEntity denotes cyclooxygenase D011451
T12 396-400 ChemicalEntity denotes PGE2 http://purl.obolibrary.org/obo/CHEBI_606564|http://purl.obolibrary.org/obo/CHEBI_15551|D015232
T10 378-394 ChemicalEntity denotes prostaglandin E2 http://purl.obolibrary.org/obo/CHEBI_15551|http://purl.obolibrary.org/obo/CHEBI_606564
T8 357-368 ChemicalEntity denotes bupivacaine http://purl.obolibrary.org/obo/CHEBI_3215|D002045
T7 83-97 ChemicalEntity denotes cyclooxygenase D011451
T5 57-73 ChemicalEntity denotes prostaglandin E2 http://purl.obolibrary.org/obo/CHEBI_15551|http://purl.obolibrary.org/obo/CHEBI_606564
T3 44-53 ChemicalEntity denotes lidocaine http://purl.obolibrary.org/obo/CHEBI_6456|D008012
T1 28-39 ChemicalEntity denotes bupivacaine http://purl.obolibrary.org/obo/CHEBI_3215|D002045
T92596 1723-1727 GeneOrGeneProduct denotes PGE2
T13 1648-1653 GeneOrGeneProduct denotes COX-2
T11 1578-1583 GeneOrGeneProduct denotes COX-1
T9 1563-1568 GeneOrGeneProduct denotes COX-2
T83862 1342-1347 GeneOrGeneProduct denotes COX-2
T6 1198-1202 GeneOrGeneProduct denotes PGE2
T44234 889-893 GeneOrGeneProduct denotes PGE2
T4 433-436 GeneOrGeneProduct denotes COX
T36658 417-431 GeneOrGeneProduct denotes cyclooxygenase
T2 396-400 GeneOrGeneProduct denotes PGE2
T39610 83-97 GeneOrGeneProduct denotes cyclooxygenase
T94111 1743-1747 DiseaseOrPhenotypicFeature denotes pain D010146
T72921 1181-1185 DiseaseOrPhenotypicFeature denotes pain D010146
T85259 1003-1007 DiseaseOrPhenotypicFeature denotes pain D010146
T41098 469-487 DiseaseOrPhenotypicFeature denotes postoperative pain D010149
T27789 330-345 DiseaseOrPhenotypicFeature denotes proinflammatory DISEASE
T48874 278-290 DiseaseOrPhenotypicFeature denotes inflammation D007249
T90464 137-141 DiseaseOrPhenotypicFeature denotes pain D010146
T60610 118-122 DiseaseOrPhenotypicFeature denotes pain D010146
T19122 491-496 OrganismTaxon denotes human

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-148 Sentence denotes The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
T2 149-160 Sentence denotes BACKGROUND:
T3 161-291 Sentence denotes In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate inflammation.
T4 292-506 Sentence denotes In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
T5 507-515 Sentence denotes METHODS:
T6 516-740 Sentence denotes Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h.
T7 741-812 Sentence denotes Oral mucosal biopsies were taken before surgery and 48 h after surgery.
T8 813-933 Sentence denotes After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 (TXB2) measurements.
T9 934-942 Sentence denotes RESULTS:
T10 943-1113 Sentence denotes The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h.
T11 1114-1295 Sentence denotes However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
T12 1296-1417 Sentence denotes Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group.
T13 1418-1584 Sentence denotes Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1.
T14 1585-1597 Sentence denotes CONCLUSIONS:
T15 1598-1793 Sentence denotes These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
T1 0-148 Sentence denotes The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
T2 149-160 Sentence denotes BACKGROUND:
T3 161-291 Sentence denotes In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate inflammation.
T4 292-506 Sentence denotes In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
T5 507-515 Sentence denotes METHODS:
T6 516-740 Sentence denotes Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h.
T7 741-812 Sentence denotes Oral mucosal biopsies were taken before surgery and 48 h after surgery.
T8 813-933 Sentence denotes After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 (TXB2) measurements.
T9 934-942 Sentence denotes RESULTS:
T10 943-1113 Sentence denotes The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h.
T11 1114-1295 Sentence denotes However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
T12 1296-1417 Sentence denotes Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group.
T13 1418-1584 Sentence denotes Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1.
T14 1585-1597 Sentence denotes CONCLUSIONS:
T15 1598-1793 Sentence denotes These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 433-436 gene:1371 denotes COX
T1 469-487 disease:C0030201 denotes postoperative pain
T2 433-436 gene:1351 denotes COX
T3 469-487 disease:C0030201 denotes postoperative pain
T4 433-436 gene:9377 denotes COX
T5 469-487 disease:C0030201 denotes postoperative pain
R1 T0 T1 associated_with COX,postoperative pain
R2 T2 T3 associated_with COX,postoperative pain
R3 T4 T5 associated_with COX,postoperative pain

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
18165598-2#141#144#gene9377 433-436 gene9377 denotes COX
18165598-2#141#144#gene1351 433-436 gene1351 denotes COX
18165598-2#141#144#gene1371 433-436 gene1371 denotes COX
18165598-2#177#195#diseaseC0030201 469-487 diseaseC0030201 denotes postoperative pain
18165598-8#50#55#gene4513 1648-1653 gene4513 denotes COX-2
18165598-8#50#55#gene5743 1648-1653 gene5743 denotes COX-2
18165598-8#145#149#diseaseC0030193 1743-1747 diseaseC0030193 denotes pain
141#144#gene9377177#195#diseaseC0030201 18165598-2#141#144#gene9377 18165598-2#177#195#diseaseC0030201 associated_with COX,postoperative pain
141#144#gene1351177#195#diseaseC0030201 18165598-2#141#144#gene1351 18165598-2#177#195#diseaseC0030201 associated_with COX,postoperative pain
141#144#gene1371177#195#diseaseC0030201 18165598-2#141#144#gene1371 18165598-2#177#195#diseaseC0030201 associated_with COX,postoperative pain
50#55#gene4513145#149#diseaseC0030193 18165598-8#50#55#gene4513 18165598-8#145#149#diseaseC0030193 associated_with COX-2,pain
50#55#gene5743145#149#diseaseC0030193 18165598-8#50#55#gene5743 18165598-8#145#149#diseaseC0030193 associated_with COX-2,pain